China NMPA Expands Fast-Track Access for Overseas Drugs

On January 7, 2026, China’s National Medical Products Administration (NMPA) issued the “Announcement on Further Optimizing the Review and Approval of Overseas-Marketed Drugs in Urgent Clinical Need” (“Announcement No. 3 of 2026”). The policy strengthens China’s access pathway for urgently needed overseas drugs by:

Expanding eligibility beyond historical urgent-need lists
Speeding key review decisions, including early alignment and faster trial-related determinations
Improving coordination across review, inspection, and temporary import mechanisms.

Regulatory Context: The Urgent Clinical Need Pathway

To understand what “Announcement No. 3 of 2026” changes in practice, it helps to start with the 2018 framework and how the pathway has operated since then.

In 2018, the NMPA established the urgent clinical need pathway through the “Announcement on Matters Related to the Review and Approval of Overseas New Drugs in Urgent Clinical Need” (“Announcement No. 79 of 2018”). This framework created a priority review route for certain overseas medicines needed by Chinese patients and relied preliminary on officially published product lists as the entry mechanism.

Under that system, 55 urgently needed products ultimately received marketing authorization through priority review and approval. “Announcement No. 3 of 2026” preserves the same access objective while reducing reliance on list-based eligibility and strengthening the mechanisms that most directly influence predictability and review timelines.

How Announcement No. 3 of 2026 Connects to the List System

The policy preserves the existing list-based mechanism while creating a clearer pathway for eligible products that are not included on historical lists.

The three batches of urgently needed drug lists issued under the 2018 framework remain valid. Applicants with products on those lists may continue to pursue priority review and approval through the established process.

The key expansion applies to products not included on prior lists. Eligible applicants may now submit directly, without waiting for a new list selection cycle. In effect, the model shifts from list-gated entry toward a more applicant-initiated pathway.

The earlier 2018 urgent-need mechanism has already been incorporated into the 2020 Priority Review and Approval working procedures, and the 2026 reform further refines how that framework operates in practice.
This signals an intent to manage the pathway under standardized procedural rules, rather than as an exceptional stand-alone arrangement.

Four Operational Changes That Matter for Overseas Applicants

Beyond eligibility, Announcement No. 3 of 2026 focuses on operational execution. The four measures below are designed to reduce uncertainty, improve timeline control, and support continuity of supply during review.

Clinical Trial Waivers for Eligible Overseas Generics

The policyexplicitly encourages high-quality overseas-marketed generics to enter China. Where evaluation requirements are met, eligible generics may be exempted from domestic clinical trials. For overseas applicants, this can materially reduce both technical barriers and time costs associated with China-specific trial planning.

Earlier CDE Alignment Through Type I Communication

The reform establishes a “pre-submission communication + tiered decision-making” model that encourages sponsors to resolve key regulatory questions before filing.

Overseas manufacturers may request Type I communication with the Center for Drug Evaluation (CDE) prior to submission.

The mechanism provides a forum to address issues that often drive cost and timeline risk in China programs, including the acceptability of overseas clinical data, the potential to waive domestic clinical trials, and eligibility for priority review.

Following dossier acceptance, the CDE applies tiered timelines:

Where China clinical trials are required, the CDE will decide within 30 days whether to approve clinical trial initiation.
Where evaluation requirements are met, applicants may submit a marketing authorization application without conducting domestic clinical trials.

Risk-Based, Coordinated Registration Inspections

The poilcy addresses a frequent operational concern for overseas manufacturers: repeated on-site inspection expectations across multiple China filings.

Drug registration inspections may be coordinated with overseas post-marketing inspections and initiated based on risk-management principles. Additionally, regulators will allocate oversight resources according to product risk and may use on-site or remote inspection approaches as appropriate.

This framework is expected to reduce the likelihood of duplicative inspection activities, rather than require separate inspections for every domestic registration.

For global quality and compliance functions, this approach supports more predictable inspection planning and reduces operational disruption associated with duplicative inspection schedules.

Optimized Temporary Import Arrangements During Review

The reform strengthens the temporary import pathway to address treatment gaps while marketing authorization applications are under review, drawing on practices from the “Beijing Pilot Zone for Rare Disease Drug Supply保障.”

Two operational elements are emphasized.

First, the process is expected to move more efficiently by shifting expert evaluation from a sequential to a parallel model. The policy also references facilitation measures such as “single customs clearance, multiple use.”

Second, the reform is intended to support supply continuity by further optimizing and accelerating the rare-disease temporary import pathway during the review period. These measures aim to better address urgent clinical treatment needs before formal approval, while improving the overall efficiency of access arrangements.

What This Means for China Market Entry Strategy

Taken together, these changes place greater emphasis on sequencing and execution. Overseas sponsors will benefit most when evidence planning, CDE engagement, inspection readiness, and temporary import strategy are managed as one integrated program.

Within this context, overseas sponsors should:

Prioritize evaluation readiness for generics. Demonstrate that evaluation requirements are met to support a domestic clinical trial exemption.
Make Type I communication your first critical milestone. Use it to confirm acceptance of overseas clinical data, the feasibility of a trial waiver, and CDE expectations prior to filing.
Build inspection strategy into the program from the outset. Establish inspection readiness early and coordinate global quality teams where risk-based overseas oversight may apply.
Integrate temporary import planning with registration strategy. Where temporary import is used, align timelines and documentation to support an efficient transition to marketing authorization and routine supply.

Sponsors most likely to benefit from this framework are those that plan China entry as an integrated, cross-functional program.

Turning Policy Optimization into Executable Compliance

Announcement No. 3 of 2026 providesoverseas manufacturers more practical and predictable routes to enter China under the urgent clinical need framework. However, faster timelines, coordinated inspections, and optimized temporary import mechanisms still depend on disciplined execution across evidence strategy, quality readiness, and early regulatory engagement.

Even with these procedural upgrades, teams can still lose months to avoidable delays -including unclear trial-waiver positioning, ineffective Type I communication that fails to resolve key questions early, or temporary import planning that does not align cleanly with the marketing authorization dossier.

This is where an experienced China regulatory partner, such as Cisema, can add value. We support overseas innovators and manufacturers with biopharmaceutical consulting services that translate policy optimization into practical execution and enable a smoother transition from urgent access to routine commercial supply in China.

To discuss how Announcement No. 3 of 2026 may apply to your portfolio, get in touch with Cisema today.

Further Information

Explore Cisema’s Pharmaceutical Consulting Services in China to learn how we support overseas innovators and manufacturers navigating China’s regulatory pathways.